Skip to main content
Caplight Logo









Santero Therapeutics

Santero Therapeutics

Private
Mont-Saint-GuibertHealthcare & Life Scienceshttps://www.santero.be/

Last Round

Series A

Jun 7, 2023

Total Funding Raised

$8.67M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Santero Therapeutics is a biotechnology company that develops first-in-class small molecule antibiotics to combat multidrug-resistant pathogens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small-molecule antibioticsdrug discovery platformantimicrobial resistanceRSH enzyme inhibitorsbacterial persistenceAMRsuperbug treatmentpreclinical therapeuticschronic infection treatmentnon-cystic fibrosis bronchiectasisNCFBantibiotic resistancebiotech startupdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Santero Therapeutics Comparables

Compare Santero Therapeutics with similar companies based on industry and business-model similarity.

Santero Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
smartbax GmbH
83%
ArrePath
79%
Telum Therapeutics
79%

Santero Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 7, 2023

Key People

Founding team and executive leadership

Mark Beards

Interim CEO

Executive Team

Santero Therapeutics Investors

Notable investors and investment history

Santero Therapeutics investors
InvestorRounds
Federal Holding and Investment CompanySeries A
Newton BiocapitalSeries A
Wallonie EntreprendreSeries A
SambrinvestSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 16, 2026

    Cuong Vuong appointed as new Chief Scientific Officer.

  • Feb 25, 2025

    Will speak at the AMR Conference in Basel on Feb 25-26, 2025.

Santero Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Santero Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Santero Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMont-Saint-Guibert
Employee Range24
Year Founded2021
Last FundingJun 7, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?